This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Digging into the Phase III Pagoda and Pavilion clinical trial data on Susvimo (ranibizumab injection) in patients with DME

Ticker(s): RHHBY

Who's the expert?

Institution: Hawaii Vision Specialist

  • Ophthalmic Surgeon and Managing Partner at Hawaii Vision Specialist
  • Specialties include comprehensive ophthalmology, medical retina (treatment including laser and injections), cataract surgery including toric and multifocal lenses, refractive laser surgery (LASIK and PRK) and cornea surgery (DSAEK and PKP)
  • Manages 120 patients annually with GA

Interview Goal
to discuss the current standard of care and the potential of Susvimo (ranibizumab injection) an alternative to eye injections being developed by Genentech for the treatment of DME.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.